Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Up 288.5% in October

Evoke Pharma, Inc. (NASDAQ:EVOK) saw a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 101,000 shares, an increase of 288.5% from the October 15th total of 26,000 shares. Based on an average daily trading volume, of 423,900 shares, the days-to-cover ratio is currently 0.2 days. Approximately 7.4% of the company’s stock are short sold.

Evoke Pharma Trading Down 14.8 %

Shares of Evoke Pharma stock traded down $0.74 on Wednesday, reaching $4.26. 175,744 shares of the company were exchanged, compared to its average volume of 129,101. Evoke Pharma has a fifty-two week low of $3.54 and a fifty-two week high of $17.88. The firm has a market capitalization of $3.49 million, a price-to-earnings ratio of -0.41 and a beta of 0.36. The stock has a fifty day moving average price of $5.08 and a 200-day moving average price of $5.52.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%. The firm had revenue of $2.55 million for the quarter.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Evoke Pharma in a research report on Tuesday. They set a “sell” rating for the company.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.